NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT05439941,A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials,https://clinicaltrials.gov/study/NCT05439941,,TERMINATED,"This is an Open-Label Extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of EDP1815 in participants with mild, moderate, and severe atopic dermatitis who have completed the treatment period of a prior clinical study (""parent study"") with EDP1815.

The current parent study of this protocol is the EDP1815-207 study; A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Cohort Study Investigating the Effect of EDP1815 in Participants for the Treatment of Mild, Moderate and Severe Atopic Dermatitis.",YES,Atopic Dermatitis,DRUG: EDP1815,"Incidence and Rate Per 100 Patient-years of Treatment-emergent Adverse Events, The long-term safety and tolerability of EDP1815 in the treatment of atopic dermatitis will be measured by evaluating the incidence and rate per 100 patient-years of treatment-emergent adverse events during the 36-week treatment period and the 4-week follow-up period of this study, and during the treatment period of this study and the relevant parent study., 40 weeks","Percentage of Participants Achieving EASI-50, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following EASI endpoints:

• Percentage of participants achieving EASI-50, 40 weeks|Percentage of Participants Achieving EASI-75, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following EASI endpoints:

• Percentage of participants achieving EASI-75, 40 weeks|Percentage of Participants Achieving EASI-90, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following EASI endpoints:

• Percentage of participants achieving EASI-90, 40 weeks|Mean Absolute Change From Baseline in EASI Score, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following EASI endpoints:

• Mean absolute change from baseline in EASI Score, 40 weeks|Mean Percentage Change From Baseline in EASI Score, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following EASI endpoints:

• Mean percentage change from baseline in EASI Score, 40 weeks|Percentage of Participants Achieving IGA of 0 or 1 With a ≥2 Point Improvement From Baseline, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA endpoints:

• Percentage of participants achieving IGA of 0 or 1 with a ≥2 point improvement from baseline, 40 weeks|Percentage of Participants Achieving IGA of 0 or 1, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA endpoints:

• Percentage of participants achieving IGA of 0 or 1, 40 weeks|Percentage of Participants Achieving IGA of 0, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA endpoints:

• Percentage of participants achieving IGA of 0, 40 weeks|Mean Absolute Change From Baseline in IGA*BSA, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA \*BSA endpoints:

• Mean absolute change from baseline in IGA\*BSA, 40 weeks|Mean Percentage Change From Baseline in IGA*BSA, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA \*BSA endpoints:

• Mean percentage change from baseline in IGA\*BSA, 40 weeks|Mean Absolute Change From Baseline in BSA, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA \*BSA endpoints:

• Mean absolute change from baseline in BSA, 40 weeks|Mean Percentage Change From Baseline in BSA, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA \*BSA endpoints:

• Mean percentage change from baseline in BSA, 40 weeks|Percentage of Participants Achieving BSA-50, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA \*BSA endpoints:

• Percentage of participants achieving BSA-50, 40 weeks|Percentage of Participants Achieving BSA-75, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following BSA endpoints:

• Percentage of participants achieving BSA-75, 40 weeks|Percentage of Participants Achieving BSA Reduction to 3% or Less, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following IGA \*BSA endpoints:

• Percentage of participants achieving BSA reduction to 3% or less, 40 weeks|Mean Absolute Change From Baseline in SCORAD, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following SCORAD endpoints:

• Mean absolute change from baseline in SCORAD, 40 weeks|Mean Percentage Change From Baseline in SCORAD, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following SCORAD endpoints:

• Mean percentage change from baseline in SCORAD, 40 weeks|Percentage of Participants Achieving SCORAD-50, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following SCORAD endpoints:

• Percentage of participants achieving SCORAD-50, 40 weeks|Percentage of Participants Achieving SCORAD-75, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following SCORAD endpoints:

• Percentage of participants achieving SCORAD-75, 40 weeks|Mean Absolute Change From Baseline in DLQI, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following DLQI endpoints:

• Mean absolute change from baseline in DLQI, 40 weeks|Mean Percentage Change From Baseline in DLQI, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following DLQI endpoints:

• Mean percentage change from baseline in DLQI, 40 weeks|Percentage of Participants Achieving a Reduction of ≥4 in the DLQI, of Those With a Score of ≥4 at Baseline, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following DLQI endpoints:

• Percentage of participants achieving a reduction of ≥4 in the DLQI, of those with a score of ≥4 at baseline, 40 weeks|Mean Absolute Change From Baseline in PP-NRS, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following PP-NRS endpoints:

• Mean absolute change from baseline in PP-NRS, 40 weeks|Percentage of Participants Achieving a Reduction of ≥2 in the PP-NRS, of Those With a Score of ≥2 at Baseline, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following PP-NRS endpoints:

• Percentage of participants achieving a reduction of ≥2 in the PP-NRS, of those with a score of ≥2 at baseline, 40 weeks|Percentage of Participants Achieving a Reduction of ≥4 in the PP-NRS, of Those With a Score of ≥4 at Baseline, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following PP-NRS endpoints:

• Percentage of participants achieving a reduction of ≥4 in the PP-NRS, of those with a score of ≥4 at baseline, 40 weeks|Mean Absolute Change From Baseline in SD-NRS, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following SD-NRS endpoints:

• Mean absolute change from baseline in SD-NRS, 40 weeks|Percentage of Participants Achieving a Reduction of ≥2 in the SD NRS, of Those With a Score of ≥2 at Baseline, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following SD-NRS endpoints:

• Percentage of participants achieving a reduction of ≥2 in the SD NRS, of those with a score of ≥2 at baseline, 40 weeks|Mean Absolute Change From Baseline in Patient Oriented Eczema Measure (POEM), The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following POEM endpoints:

• Mean absolute change from baseline in Patient Oriented Eczema Measure (POEM), 40 weeks|Mean Percentage Change From Baseline in Patient Oriented Eczema Measure (POEM), The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following POEM endpoints:

• Mean percentage change from baseline in Patient Oriented Eczema Measure (POEM), 40 weeks|Percentage of Participants Achieving a Reduction of ≥4 in the POEM Score, of Those With a Score of ≥4 at Baseline, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following POEM endpoints:

• Percentage of participants achieving a reduction of ≥4 in the POEM score, of those with a score of ≥4 at baseline, 40 weeks|Number of Courses Per Patient-year of Any Rescue Medication (Not Including Antibacterial Therapy), The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following Rescue therapy use endpoints:

• Number of courses per patient-year of any rescue medication (not including antibacterial therapy), 40 weeks|Number of Courses Per Patient-year of Topical Corticosteroids of Any Potency, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following Rescue therapy use endpoints:

• Number of courses per patient-year of topical corticosteroids of any potency, 40 weeks|Number of Courses Per Patient-year of Topical Tacrolimus (0.1%), Topical Pimecrolimus (1%) or Grade VII Topical Corticosteroid, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following Rescue therapy use endpoints:

• Number of courses per patient-year of topical tacrolimus (0.1%), topical pimecrolimus

(1%) or grade VII topical corticosteroid, 40 weeks|Number of Courses Per Patient Year of Moderate Potency (Grade IV and V) Topical Steroids, The efficacy of long-term treatment with EDP1815 in the treatment of Atopic Dermatitis will be measured using the following Rescue therapy use endpoints:

• Number of courses per patient year of moderate potency (grade IV and V) topical steroids, 40 weeks",,"Evelo Biosciences, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE2,287,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EDP1815-208|2022-000284-48,2022-06-06,2023-05-25,2023-06-07,2022-06-30,2023-07-14,2023-09-07,"USA-131, Birmingham, Alabama, 35244, United States|USA 112, Fountain Valley, California, 92708, United States|USA 123, Fremont, California, 94538, United States|USA -101, Fort Lauderdale, Florida, 33308, United States|USA-124, Jacksonville, Florida, 32216, United States|USA-108, Miami, Florida, 33165, United States|USA-120, Miami, Florida, 33175, United States|USA-105, Miramar, Florida, 33027, United States|USA-102, Orlando, Florida, 32801, United States|USA-115, Sweetwater, Florida, 33172, United States|USA-106, Tampa, Florida, 33613, United States|USA-126, Tampa, Florida, 33613, United States|USA-111, Clarksville, Indiana, 47129, United States|USA-116, Louisville, Kentucky, 40241, United States|USA-119, Baton Rouge, Louisiana, 70806, United States|USA-109, Metairie, Louisiana, 70006, United States|USA-125, Silver Spring, Maryland, 20902, United States|USA-121, Columbus, Ohio, 43221, United States|USA-128, Concord, Ohio, 44077, United States|USA-104, Portland, Oregon, 97239, United States|USA-127, Memphis, Tennessee, 38119, United States|USA-117, Frisco, Texas, 75034, United States|USA-110, Pflugerville, Texas, 78660, United States|USA-113, Bellevue, Washington, 98004, United States|AUS-102, Carlton, Australia|AUS-104, Kogarah, Australia|AUS-101, Melbourne, Australia|AUS-106, Woolloongabba, Australia|BGR-105, Pleven, Bulgaria|BGR-104, Sevlievo, Bulgaria|BGR-101, Sofia, Bulgaria|BGR-103, Sofia, Bulgaria|CAN-109, Barrie, Canada|CAN-108, Edmonton, Canada|CAN-105, Markham, Canada|CAN-104, Mississauga, Canada|CAN-101, Ottawa, Canada|CAN-107, Richmond Hill, Canada|CAN-103, Surrey, Canada|CAN-106, Waterloo, Canada|CAN-111, Winnipeg, Canada|DEU-105, Berlin, Germany|DEU-106, Erlangen, Germany|DEU-102, Frankfurt am Main, Germany|DEU-104, Gera, Germany|DEU-101, Hamburg, Germany|DEU-103, Heidelberg, Germany|POL-104, Gdańsk, Poland|POL-106, Gdynia, Poland|POL-107, Katowice, Poland|POL-101, Lublin, Poland|POL-102, Warszawa, Poland|POL-103, Wrocław, Poland|POL-105, Łódź, Poland","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/41/NCT05439941/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/41/NCT05439941/SAP_001.pdf"
